SuperworthBiomea Fusion BMEA
Drug Manufacturers - General, Healthcare
$0.60
+2.58%
- Market cap
- $43.5M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $25.3M+39% | $30.9M+50% | $33.8M+39% | $31.8M+45% | $27.2M+8% | $25.2M−18% | $22.9M−32% | $16.6M−48% | $14.4M−47% | $8.1M−68% | $9.1M−60% | $9.1M−45% |
| SG&A | $5.8M+10% | $6.5M+13% | $7.3M+29% | $7.1M+24% | $6.8M+18% | $4.8M−25% | $6.8M−6% | $4.7M−33% | $4.2M−38% | $3.6M−25% | $3.7M−46% | $3.6M−23% |
| −$31.1M+33% | −$37.3M+42% | −$41.1M+37% | −$38.9M+41% | −$34M+9% | −$30.1M−19% | −$29.7M−28% | −$21.3M−45% | −$20.8M−39% | −$11.7M−61% | −$12.8M−57% | −$12.8M−40% | |
| Net income | −$28.4M+24% | −$34.9M+38% | −$39.1M+35% | −$37.3M+50% | −$32.8M+15% | −$29.3M−16% | n/a | n/a | n/a | n/a | n/a | n/a |
| −$0.80+3% | −$0.98+14% | −$1.09+11% | −$1.03+47% | −$0.91+14% | −$0.81−17% | −$0.80−27% | −$0.51−51% | −$0.27−70% | n/a | −$0.17−79% | −$0.12−77% | |
| 35.7M+22% | 35.8M+21% | 35.9M+21% | 36M+2% | 36.2M+2% | 36.3M+1% | 36.6M+2% | 40.6M+13% | 59.8M+65% | 71.3M+97% | 72.3M+97% | 72.4M+78% |
Diluted shares: Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Biomea Fusion's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BMEABiomea Fusion | $43.5M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $69M | 11.1× | 14.5× | 0.4× | −3% | 3.7% |
More on Biomea Fusion
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .